12:00 AM
 | 
Mar 24, 2008
 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments

Nomura's investments
Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds it can go up to a total of $30-$40 million per company. Prior to 2004, Phase4's share in a round was unlikely to exceed $15 million, whereas post-2004, it is more likely to be on the order of $25 million. Over the years, Nomura has completely exited nine of its investments, including six from M&A and three from IPOs, and partially exited four undisclosed investments. The list below does not include medical device companies. (A) Completely exited; Source: Nomura Phase4 Ventures; BioCentury Online Intelligence - BCIQ
Company Description Year of initial investment Total raised in financings involving Nomura Additional investors
Avant (NASDAQ:AVAN), merged with Celldex (A) Developing vaccines leveraging bacterial vector delivery technologies 1999 $11M PIPE, 1999 Institutional investors
DrugAbuse Sciences, certain assets acquired by elbion in 2007 Developed therapeutics to treat and prevent drug addictions 1999 $22M series D, 1999 3i; ABN AMRO; Auriga Ventures; CDC Ixis Innovation; Edmond de Rothschild Investment Partners; Financiere de Brienne; Parnib Belgie; Partech International; SG Asset Management
$24M series E, 2001 3i; Canaan Partners
$6M...

Read the full 1158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >